公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2020 | Budesonide/formoterol anti-inflammatory reliever and maintenance or fluticasone propionate/ salmeterol plus as-needed, short-acting β2 agonist: Real-world effectiveness in patients without optimally controlled asthma (react) study | Cheng S.-L.; Ho M.-L.; Lai Y.-F.; HAO-CHIEN WANG ; Hsu J.-Y.; Liu S.-F.; Huang M.-S.; Lee C.-H.; Lin C.-H.; Hang L.-W.; Liu Y.-C.; Yang K.-Y.; Wang J.-H. | Drug Design, Development and Therapy | 6 | 7 | |
2008 | High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy | Perng R.-P.; CHIH-HSIN YANG ; Chen Y.-M.; Chang G.-C.; Lin M.-C.; Hsieh R.-K.; Chu N.-M.; Lai R.-S.; Su W.-C.; Tsao C.-J.; Hsia T.-C.; Chen H.-C.; Chen C.-H.; Huang M.-S.; Wang J.-L.; Ho M.-L.; Chung C.-Y.; CHONG-JEN YU ; Chang W.-C.; Kuo H.-P.; Yu C.-T.; ZHONG-ZHE LIN ; Kao W.-Y. | Lung Cancer | 28 | 26 |